BPC-157: what human research does and does not show
BPC-157 is a lab-made peptide that is popular online for injury recovery. Most of the research is in animals. A 2026 systematic review found only three small human studies, 30 people in total, judged to be of poor quality, with very low certainty of evidence. It is not an FDA-approved medicine. This page does not recommend or advise against any product and gives no dosing.
Sources checked against Europe PMC abstracts and FDA/DailyMed label text: Nov 17, 2026; full text not read for abstract-only claims (recheck on publication date)
Quick answer
BPC-157 is a lab-made peptide that is popular online for injury recovery. Most of the research is in animals. A 2026 systematic review found only three small human studies, 30 people in total, judged to be of poor quality, with very low certainty of evidence. It is not an FDA-approved medicine. This page does not recommend or advise against any product and gives no dosing.
What BPC-157 is
BPC-157 (“body protection compound-157”) is described in the literature as a synthetic pentadecapeptide, a chain of 15 amino acids. It is promoted for injury recovery. Source: systematic review, 2026.
What the research shows

Human BPC-157 studies
Animal studies. A 2026 narrative review says BPC-157 has the largest body of direct musculoskeletal preclinical evidence among the peptides it covered, mostly in small animals. Animal results do not show the same effects or safety in people. Source: Investigational peptides in orthopaedic practice, 2026.
Human studies. A systematic review searched four databases (Embase, PubMed, Cochrane, ClinicalTrials.gov) up to June 1, 2026. Three studies (n=30) met its criteria: a retrospective study of intra-articular injections for knee pain (n=16), a retrospective pilot study of intravesical use for interstitial cystitis (n=12) and a prospective pilot study of intravenous safety (n=2). They reported symptom improvement in most participants without treatment-related adverse events, but were judged to be of poor methodological quality, and the certainty of evidence was rated very low. The authors concluded it should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials. Source: systematic review, 2026.
The orthopaedic narrative review adds that validated dosing, pharmacokinetic and long-term safety data are lacking, and that marketed products raise concerns about identity, purity, concentration, sterility and manufacturing consistency. It says none of these agents has an FDA-approved musculoskeletal indication. Source: narrative review, 2026.
Regulatory status
FDA lists BPC-157 among the bulk drug substances in Category 2 for compounding, which are those that may present significant safety risks. For BPC-157, FDA cites possible immunogenicity risk for certain routes, peptide-related impurity and characterization complexities, and no or only limited safety information, so it cannot tell whether the drug would cause harm in humans. Source: FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (no update date shown; read Nov 17, 2026). FDA’s Pharmacy Compounding Advisory Committee agenda for July 23-24, 2026 included votes on whether BPC-157 should be placed on the 503A bulks list. Source: FDA PCAC agenda. Status can change; regulatory owner to confirm at publication.
How to talk with a clinician
If you are thinking about BPC-157, or already use it, tell your clinician. Useful things to bring:
- The product name, where it came from and any label or testing information.
- What it is for and what else you have tried.
- All medicines, supplements, conditions and any symptoms.
If you compete in sport, ask about anti-doping rules.
What this does not establish
The studies do not show that BPC-157 works or that it is safe. The absence of reported side effects in 30 people in poor-quality studies is not evidence of safety. Animal findings cannot be assumed to apply to people.
FAQs
What does human research show about BPC-157? A 2026 systematic review found three small, poor-quality studies in 30 people and rated the certainty of evidence very low.
Is BPC-157 FDA approved? The 2026 systematic review describes it as lacking regulatory approval for human use.
Sources
- Human evidence for BPC-157 in orthopaedic and regenerative medicine: systematic review, 2026
- Investigational peptides in orthopaedic practice: BPC-157, thymosin beta-4 and TB-500, 2026
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
- FDA, Pharmacy Compounding Advisory Committee agenda, July 23-24, 2026